KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalMarket CapitalizationNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Halozyme Therapeutics (HALO) Return on Capital Employed: 2009-2025

Historic Return on Capital Employed for Halozyme Therapeutics (HALO) over the last 17 years, with Sep 2025 value amounting to 0.57%.

  • Halozyme Therapeutics' Return on Capital Employed rose 32.00% to 0.57% in Q3 2025 from the same period last year, while for Sep 2025 it was 0.57%, marking a year-over-year increase of 32.00%. This contributed to the annual value of 0.31% for FY2024, which is 11.00% up from last year.
  • Halozyme Therapeutics' Return on Capital Employed amounted to 0.57% in Q3 2025, which was up 65.38% from 0.34% recorded in Q2 2025.
  • In the past 5 years, Halozyme Therapeutics' Return on Capital Employed registered a high of 0.57% during Q3 2025, and its lowest value of 0.15% during Q3 2022.
  • Moreover, its 3-year median value for Return on Capital Employed was 0.23% (2024), whereas its average is 0.26%.
  • Examining YoY changes over the last 5 years, Halozyme Therapeutics' Return on Capital Employed showed a top increase of 45bps in 2021 and a maximum decrease of 84bps in 2021.
  • Over the past 5 years, Halozyme Therapeutics' Return on Capital Employed (Quarterly) stood at 0.27% in 2021, then declined by 11bps to 0.16% in 2022, then climbed by 4bps to 0.20% in 2023, then grew by 8bps to 0.28% in 2024, then spiked by 32bps to 0.57% in 2025.
  • Its last three reported values are 0.57% in Q3 2025, 0.34% for Q2 2025, and 0.30% during Q1 2025.